NCT02660034: The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors

NCT02660034
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: BRCA+, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Any patient with tumors that have DNA damage repair deficiencies susceptible to treatment with a PARP inhibitor qualify for Part A of the study; Only TNBC patients with germline or somatic BRCA1/2 mutations are eligible for Part B of the study (see Arm 2)
Exclusions: Symptomatic central nervous system (CNS) metastasis
https://ClinicalTrials.gov/show/NCT02660034

Comments are closed.

Up ↑